Coy Heldermon

Coy Heldermon, M.D., Ph.D.

Associate Professor

Department: MD-HEMATOLOGY/ONCOLOGY
Business Phone: (352) 273-8008

About Coy Heldermon

Dr. Heldermon is an associate professor of medicine, board certified medical oncologist with expertise in the treatment of breast cancer. He is a member of the American Society of Hematology and the American Society of Clinical Oncology. His research expertise is in the use of gene replacement and stem cell therapies for the treatment of inherited disorders such as lysosomal storage diseases. He also studies the spread of stem cells from maternal or malignant sources using mouse models.

Board Certifications

  • Internal Medicine
    American Board of Internal Medicine
  • Oncology
    American Board of Internal Medicine

Clinical Profile

Specialties
  • Medicine
Subspecialties
  • Oncology
Areas of Interest
  • Breast cancer
  • Cancer – resources
  • Gaucher disease
  • Mucopolysaccharidosis type III
  • Stem cell research

Research Profile

Open Researcher and Contributor ID (ORCID)

0000-0002-2148-2868

Publications

2021
Five-Year Breast Surgeon Experience in LYMPHA at Time of ALND for Treatment of Clinical T1-4N1-3M0 Breast Cancer.
Annals of surgical oncology. [DOI] 10.1245/s10434-021-10551-8. [PMID] 34365563.
2021
Reflections of Healthcare Experiences of African Americans With Sickle Cell Disease or Cancer: A Qualitative Study.
Cancer nursing. 44(1):E53-E61 [DOI] 10.1097/NCC.0000000000000750. [PMID] 31743153.
2021
Site-specific modifications to AAV8 capsid yields enhanced brain transduction in the neonatal MPS IIIB mouse.
Gene therapy. 28(7-8):447-455 [DOI] 10.1038/s41434-020-00206-w. [PMID] 33244179.
2021
The beta-glucuronidase intracisternal A particle insertion model results in similar overall MPSVII phenotype as the single base deletion model when on the same C57BL/6J mouse background.
Molecular genetics and metabolism reports. 27 [DOI] 10.1016/j.ymgmr.2021.100727. [PMID] 33604242.
2020
An Erythritol-Sweetened Beverage Induces Satiety and Suppresses Ghrelin Compared to Aspartame in Healthy Non-Obese Subjects: A Pilot Study.
Cureus. 12(11) [DOI] 10.7759/cureus.11409. [PMID] 33194505.
2020
Generation of Induced Pluripotent Stem Cells from a Female Patient with a Xq27.3-q28 Deletion to Establish Disease Models and Identify Therapies.
Cellular reprogramming. 22(4):179-188 [DOI] 10.1089/cell.2020.0012. [PMID] 32608992.
2020
Multiscale Detection of Cancerous Tissue in High Resolution Slide Scans
Advances in Visual Computing. 139-153 [DOI] 10.1007/978-3-030-64559-5_11.
2020
Obesity and STING1 genotype associate with 23-valent pneumococcal vaccination efficacy.
JCI insight. 5(9) [DOI] 10.1172/jci.insight.136141. [PMID] 32376795.
2020
The Value of Integrating Fluorescent Imaging and Immunohistochemistry for Future Anatomical Studies in Aesthetic Surgery: Lessons From the Cerebrospinal Fluid (CSF) Circulatory System of Human Nerves and Brain.
Aesthetic surgery journal. [DOI] 10.1093/asj/sjaa247. [PMID] 32827254.
2019
A non-catalytic function of carbonic anhydrase IX contributes to the glycolytic phenotype and pH regulation in human breast cancer cells.
The Biochemical journal. 476(10):1497-1513 [DOI] 10.1042/BCJ20190177. [PMID] 31072911.
2019
A novel proteotoxic combination therapy for EGFR+ and HER2+ cancers.
Oncogene. 38(22):4264-4282 [DOI] 10.1038/s41388-019-0717-6. [PMID] 30718919.
2019
Disulfide bond-disrupting agents activate the tumor necrosis family-related apoptosis-inducing ligand/death receptor 5 pathway.
Cell death discovery. 5 [DOI] 10.1038/s41420-019-0228-9. [PMID] 31839995.
2019
Projected clinical benefit of surveillance imaging for early detection and treatment of breast cancer metastases.
The breast journal. 25(1):75-79 [DOI] 10.1111/tbj.13153. [PMID] 30548515.
2018
Differential expression and function of CAIX and CAXII in breast cancer: A comparison between tumorgraft models and cells.
PloS one. 13(7) [DOI] 10.1371/journal.pone.0199476. [PMID] 29965974.
2018
Epidemiological, Clinical, and Histopathological Features of Breast Cancer in Haiti.
Journal of global oncology. 4:1-9 [DOI] 10.1200/JGO.17.00135. [PMID] 30241242.
2018
UFH-001 cells: A novel triple negative, CAIX-positive, human breast cancer model system.
Cancer biology & therapy. 19(7):598-608 [DOI] 10.1080/15384047.2018.1449612. [PMID] 29561695.
2017
Disulfide bond disrupting agents activate the unfolded protein response in EGFR- and HER2-positive breast tumor cells.
Oncotarget. 8(17):28971-28989 [DOI] 10.18632/oncotarget.15952. [PMID] 28423644.
2017
Periorbital and Temporal Anatomy, “Targeted Fat Grafting,” and How a Novel Circulatory System in Human Peripheral Nerves and Brain May Help Avoid Nerve Injury and Blindness During Routine Facial Augmentation.
Aesthetic surgery journal. 37(8):969-973 [DOI] 10.1093/asj/sjx089. [PMID] 28595323.
2016
A phase I study of thymoglobulin for relapsed or refractory multiple myeloma.
Leukemia & lymphoma. 57(2):453-455 [DOI] 10.3109/10428194.2015.1049170. [PMID] 25971909.
2016
Development of a Breast Cancer Treatment Program in Port-au-Prince, Haiti: Experiences From the Field.
Journal of global oncology. 2(1):9-14 [DOI] 10.1200/JGO.2015.000364. [PMID] 28717677.
2016
Epithelial-to-mesenchymal transition confers pericyte properties on cancer cells.
The Journal of clinical investigation. 126(11):4174-4186 [DOI] 10.1172/JCI86623. [PMID] 27721239.
2016
Mucopolysaccharidosis IIIB confers enhanced neonatal intracranial transduction by AAV8 but not by 5, 9 or rh10.
Gene therapy. 23(3):263-71 [DOI] 10.1038/gt.2015.111. [PMID] 26674264.
2016
Pigmentation of the Tongue with Lapatinib Treatment in a Patient with Advanced Breast Cancer: A Case Report.
Cancer treatment communications. 7:1-3 [PMID] 27110490.
View on: PubMed
2016
Preferred transduction with AAV8 and AAV9 via thalamic administration in the MPS IIIB model: A comparison of four rAAV serotypes.
Molecular genetics and metabolism reports. 6:48-54 [DOI] 10.1016/j.ymgmr.2015.11.006. [PMID] 27014573.
2015
High resolution functional photoacoustic tomography of breast cancer.
Medical physics. 42(9):5321-8 [DOI] 10.1118/1.4928598. [PMID] 26328981.
2015
Novel agents that downregulate EGFR, HER2, and HER3 in parallel.
Oncotarget. 6(12):10445-59 [PMID] 25865227.
View on: PubMed
2014
Ado-trastuzamab emtansine associated hyponatremia and intracranial hemorrhage.
Acta oncologica (Stockholm, Sweden). 53(10):1434-6 [DOI] 10.3109/0284186X.2014.920959. [PMID] 24834794.
2014
Mucopolysaccharidosis III (Sanfilippo Syndrome)- disease presentation and experimental therapies.
Pediatric endocrinology reviews : PER. 12 Suppl 1:133-40 [PMID] 25345095.
View on: PubMed
2014
TRIM29 suppresses TWIST1 and invasive breast cancer behavior.
Cancer research. 74(17):4875-87 [DOI] 10.1158/0008-5472.CAN-13-3579. [PMID] 24950909.
2013
Comparing Ic6 and Thalamic Aav5 Injections On Mps Iiib Model
Molecular Genetics and Metabolism. 108(2) [DOI] 10.1016/j.ymgme.2012.11.133.
2013
Differences in Aav Serotype Dependent Distribution and Tropism Exist Within the Cns of Wild Type and Mutant Mice in the Mpsiiib Mouse Model
Molecular Therapy. 21
2013
Differences in Aav Serotype Dependent Distribution and Tropism Within the Cns of Wild Type and Mutant Mice in the Mps Iiib Mouse Model
Molecular Genetics and Metabolism. 108(2) [DOI] 10.1016/j.ymgme.2012.11.096.
2013
Disease correction by combined neonatal intracranial AAV and systemic lentiviral gene therapy in Sanfilippo Syndrome type B mice.
Gene therapy. 20(9):913-21 [DOI] 10.1038/gt.2013.14. [PMID] 23535899.
2012
Effects of Minozak And/Or Genistein On the Central Nervous System of Sanfilippo Syndrome Type B Mice
Molecular Genetics and Metabolism. 105(2) [DOI] 10.1016/j.ymgme.2011.11.060.
2010
Therapeutic Efficacy of Bone Marrow Transplant, Intracranial Aav-Mediated Gene Therapy, Or Both in the Mouse Model of Mps Iiib
Molecular Therapy. 18(5):873-880 [DOI] 10.1038/mt.2010.17. [PMID] 20179679.
2007
Development of sensory, motor and behavioral deficits in the murine model of Sanfilippo syndrome type B.
PloS one. 2(8) [PMID] 17712420.
View on: PubMed
2001
Site-directed mutation of conserved cysteine residues does not inactivate the Streptococcus pyogenes hyaluronan synthase.
Glycobiology. 11(12):1017-24 [PMID] 11805074.
View on: PubMed
2001
Topological organization of the hyaluronan synthase from Streptococcus pyogenes.
The Journal of biological chemistry. 276(3):2037-46 [PMID] 11024012.
View on: PubMed
1999
Kinetic characterization of the recombinant hyaluronan synthases from Streptococcus pyogenes and Streptococcus equisimilis.
The Journal of biological chemistry. 274(7):4246-53 [PMID] 9933624.
View on: PubMed
1999
Properties of the hyaluronan synthase from group A Streptococcus pyogenes.
Biochemical Society transactions. 27(2):105-9 [PMID] 10093716.
View on: PubMed
1995
Expression and DNA binding of the human 52 kDa Ro/SSA autoantigen.
The Biochemical journal. 305 ( Pt 2):359-62 [PMID] 7832745.
View on: PubMed
Mechanistic Elucidation of the Antitumor Properties of a Novel Death Receptor 5 Activator
. [DOI] 10.1101/700906.

Grants

May 2021 ACTIVE
Novel Mechanism of Action and Translational Potential of the HDAC Inhibitor SR-4370 for Treating Breast Cancer
Role: Co-Investigator
Funding: FL DEPT OF HLTH BIOMED RES PGM/J&E KING
Jun 2020 ACTIVE
Novel immunologic therapy of soft tissue sarcoma
Role: Principal Investigator
Funding: FL DEPT OF HLTH LIVE LIKE BELLA
Jun 2020 ACTIVE
Lipidnanoparticle vaccines targeting metastatic lung cancer from osteosarcoma
Role: Co-Investigator
Funding: FL DEPT OF HLTH BANKHEAD-COLEY CANCER RE
Jun 2020 ACTIVE
Molecular mechanisms and pharmacologic targeting of lipogenesis in breast cancer
Role: Other
Funding: FL DEPT OF HLTH BIOMED RES PGM/J&E KING
May 2020 – Jun 2021
Task Order #7 – AAV-mediated therapy for MPS IIIB
Role: Principal Investigator
Funding: LACERTA THERAPEUTICS
Jul 2019 – Jun 2021
Novel oral targeted breast carcinoma vaccine
Role: Co-Investigator
Funding: FL BREAST CANCER FOU
Jul 2018 – Dec 2020
A new approach for eradicating metastatic, drug-resistant breast cancers
Role: Co-Investigator
Funding: OCALA ROYAL DAMES FOR CANCER RESEARCH
Feb 2018 – Jan 2019
Novel isoform-selective HDAC inhibitor for enhancing cancer immunotherapy against breast cancer
Role: Co-Investigator
Funding: FL BREAST CANCER FOU
Sep 2017 – Jun 2021
UFHCC Triple Negative Breast Cancer (TNBC) Pilot Project Program
Role: Project Manager
Funding: MULTIPLE SPONSORS
Aug 2017 ACTIVE
Optimizing AAV Vectors for Central Nervous System transduction
Role: Principal Investigator
Funding: NATL INST OF HLTH NINDS
May 2017 – Jun 2018
Gene therapy with intracranial delivery of capsid enhanced AAV NAGLU
Role: Principal Investigator
Funding: FUNDACJA SANFILIPPO
Mar 2017 ACTIVE
Neural and mesenchymal stem cell mediated gene therapy for Sanfilippo Syndrome B
Role: Principal Investigator
Funding: THE SANFILIPPO CHILDRENS RES FOU
Mar 2017 – Mar 2019
Neural and mesenchymal stem cell mediated gene therapy for Sanfilippo Syndrome B
Role: Principal Investigator
Funding: CURE SANFILIPPO FOU
May 2016 – Jun 2019
Gene therapy with intracranial delivery of capsid enhanced AAV NAGLU
Role: Principal Investigator
Funding: SAN FILIPPO CHILDRENS FOU
May 2016 – Jun 2018
Gene therapy with intracranial delivery of capsid enhanced AAV NAGLU
Role: Principal Investigator
Funding: SANFILIPPO INITIATIVE E V
Mar 2016 – Jun 2021
Early markers of subclinical pulmonary vascular radiation toxicity in breast cancer
Role: Co-Investigator
Funding: FL DEPT OF HLTH BANKHEAD-COLEY CANCER RE
Mar 2016 – Aug 2019
PHARMACOLOGIC INHIBITION OF ACETYLTRANSFERASE CBP/P300 AS ANEW THERAPEUTIC APPROACH FOR BREAST CANCER
Role: Project Manager
Funding: FL DEPT OF HLTH BIOMED RES PGM/J&E KING
Dec 2015 ACTIVE
Miscellaneous Donors
Role: Principal Investigator
Funding: MISCELLANEOUS DONORS
Jun 2015 – Sep 2019
Novel agents that simultaneously downregulate Her2, EGFR, and Her3
Role: Project Manager
Funding: US ARMY MED RES ACQUISITION
Apr 2015 – Jun 2021
Clinical and Translational Science Institute (CTSI)
Role: Project Manager
Funding: UF DIV OF SPONSORED RES MATCHING FUNDS
Feb 2015 ACTIVE
UF Health Cancer Center Pilot Project Grants funded through the Florida Consortium of National Cancer Institute Centers Program
Role: Project Manager
Funding: UF HEALTH SHANDS HOSPITAL
Feb 2015 – Jan 2017
Patient derived xenograft model studies of metastases in triple negative breast cancer
Role: Principal Investigator
Funding: UF FOU
Jul 2014 – Dec 2018
The Role of the Intestinal Microbiota in the Development of Anxiety and Depression in Breast Cancer Patients Receiving Chemotherapy.
Role: Project Manager
Funding: FL BREAST CANCER FOU
Jun 2014 – May 2016
Endobronchial Photoacoustic Microscopy for Staging of Lung Cancer
Role: Project Manager
Funding: US ARMY MED RES ACQUISITION
Apr 2013 – Mar 2019
Carbonic anhydrase and pH control in breast cancer cells
Role: Project Manager
Funding: NATL INST OF HLTH NCI
Mar 2010 – Feb 2016
Transplacental stem cell transplantation and evaluation of therapeutic effect
Role: Principal Investigator
Funding: NATL INST OF HLTH NIDDK
Jul 2007 ACTIVE
Breast Cancer Research
Role: Project Manager
Funding: UF FOU
Apr 2002 – Jul 2017
02032110
Role: Principal Investigator
Funding: NATL CANCER INST OF CANADA

Education

Fellowship – Oncology
2008 · Barnes-Jewish Hospital
Residency – Internal Medicine
2004 · Barnes – Jewish Hospital
Internship – Obstetrics and Gynecology
2002 · Stanford Hospital
Medical Degree
2002 · University of Oklahoma

Teaching Profile

Courses Taught
2019
PHA6136 Clinical Applications of Precision Medicine: Oncology
2017-2018,2021
GMS6847 Translational Research and Therapeutics: Bench, Bedside, Community, & Policy
2018
GMS7979 Advanced Research
2018
MDC7200 Medicine Clerkship
2018
BME7980 Research for Doctoral Dissertation
2010
IDH4917 Undergrad Research
2010
IDH4905 Individual Work
2021
PHA6935 Selected Topics in Pharmacy

Contact Details

Phones:
Business:
(352) 273-8008
Emails: